Clinical Trial Update: Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy and safety of agalsidase beta in heterozygous females with Fabry disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• FABRAZYME (Agalsidase beta)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Fabry Disease | Phase 4 | Status: UNKNOWN